This $539,218 Project Grant, awarded on September 17, 2024 by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), supports research efforts at the University of Pennsylvania to develop and validate novel prediction models and identify novel subphenotypes for interstitial lung disease (ILD) in patients with myositis.
The key objectives are to: 1) Utilize a large, diverse patient cohort to develop a progression-free survival prediction model for myositis-ILD using clinical data and biomarkers like HLA genotypes; and 2) Apply cluster analysis to clinical, genomic, and serological data to identify distinct myositis-ILD subphenotypes with different pathobiology, treatment responsiveness, and outcomes. This work aims to establish a validated clinical signature to enable precision therapy for myositis-ILD patients and generate new treatment approaches. The research leverages existing clinical and biorepository data from five U.S. myositis-ILD referral centers.
Generated 1/28/25, 11:00 AM